Model-informed Drug Repurposing - Applications for COVID-19
The global scientific community’s scramble to rapidly find therapeutics for COVID-19 has been reassuring, but unfortunately also chaotic. There are now almost 700 clinical trials conducted, planned or in progress – many with poor rationale for the drugs and dosing regimens being investigated. Now more than ever, the clinical and quantitative pharmacology community must use their state-of-the-art tools and expertise to efficiently identify the right drug at the right dose for the right patient to fight COVID-19.
In this webinar co-hosted by Pharmacometrics Africa and Certara, you will learn about the importance of integrating clinical pharmacology and translational medicine principles in COVID-19 dosing strategy and study design. We will demonstrate pharmacokinetic pharmacodynamic (PKPD) simulation tools available on covidpharmacology.com using recently completed analyses for ivermectin, chloroquine, and lopinavir/ritonavir. At the end of this session, users will be able to explore the software, code and simulation tools on their own.
Thursday, 14 May 2020
Colin Pillai runs two social ventures that develop scientific capability in drug discovery and development in low- and middle-income countries. Previously, he worked as a pharmacometrician and a senior leader at Roche and Novartis in Switzerland. He acquired his clinical and research experience in hospital and community pharmacy, academia and at the South African Medical Research Council’s Tuberculosis Research programme running Phase 1 clinical trials. Colin is a Honorary Professor at UCT, a Honorary Fellow of the Royal College of Physicians and a Senior Advisor on capacity development for global health to the Bill and Melinda Gates Foundation.
Adeniyi Olagunju is a Senior Lecturer, Wellcome Trust Fellow and Affiliate of the African Academy of Sciences at Obafemi Awolowo University, Nigeria. He has 10 years of teaching and research experience combined with 12 years as a licensed Pharmacist in Nigeria. He holds a PhD in Pharmacology from the University of Liverpool. His primary research interest is infectious diseases pharmacology with a focus on generating PK and PD data on special population cohorts in Africa, including pregnant and lactating women. In addition to leading pharmacometrics development efforts in his institution, he coordinates the Pharmacometrics Africa webinar series.
Mike Dodds is executive director of Integrated Drug Development at Certara. He has been working in the pharmacometrics field since 2005. Previously, he worked for ZymoGenetics in the Department of Pharmacokinetics and Pharmacodynamics, providing predictive modeling support for emerging drug candidates in the areas of autoimmunity, coagulation and oncology. Prior to that, he worked for Amgen, providing modeling and simulation expertise to guide development program decisions around target selection, preclinical-to-clinical translation, dose and regimen selection, and biosimilar development. Mike has authored 20+ peer-reviewed articles, has presented at ACoP, ASCPT, PAGE, and holds two patents. He received his BS in Chemical Engineering and BS in Biochemistry from North Carolina State University, MS in Chemical Engineering from Montana State University, and PhD in Bioengineering from the University of Washington.
Samer Mouksassi is Senior Director of Integrated Drug Development at Certara. Since 2007, he has been responsible for implementing model-based drug development, PK/PD modeling and simulation, advanced statistics, realistic clinical trial simulations to help sponsors with regulatory submissions and decisions with the FDA, MEA and Japan. Since 2014, he has been dedicated to the Knowledge Integration Quantitative Sciences team at the Bill & Melinda Gates Foundation to support programs for the Maternal, Neonatal, and Child Health Initiative. Samer is currently Associate Professor of Pharmacometrics and Clinical Trial Design at Université de Montréal and Lebanese American University. Samer received his Pharm.D from Lebanese University, and Ph.D. in PK/PD modeling from Université de Montréal. He has co-authored over 100 scientific communications.
Yuan Xiong is Director of Integrated Drug Development at Certara. With 10 years of experience in pharmaceutical R&D, Dr. Xiong has in-depth hands-on experience of population PK/PD modeling, clinical trial simulations, and systems pharmacology in therapeutic areas such as infectious diseases, autoimmune disorders, and oncology. Additionally, she has strong research & development experience in mathematical modeling of complex biological and physiological systems, disease models, cell signaling pathways, stochastic simulations, and biomedical image processing and analysis. Dr. Xiong received her PhD in electrical and computer engineering from The Johns Hopkins University. She has published many papers in the past ten years, collaborating and communicating experience working in multi-disciplinary teams of quantitative and computational scientists, clinicians and life scientists.